+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biopharmaceutical CMO & CRO Market by Service Type, Product Type, Application, End User - Global Forecast to 2030- Product Image
Biopharmaceutical CMO & CRO Market by Service Type, Product Type, Application, End User - Global Forecast to 2030- Product Image
Sale

Biopharmaceutical CMO & CRO Market by Service Type, Product Type, Application, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010880
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biopharmaceutical CMO & CRO Market grew from USD 95.65 billion in 2024 to USD 113.74 billion in 2025. It is expected to continue growing at a CAGR of 18.22%, reaching USD 261.14 billion by 2030.

Pioneering the Future of Biopharmaceutical Outsourcing

In an era defined by rapid innovation and increasing complexity, the biopharmaceutical contract research and contract manufacturing landscape has never been more pivotal to the success of therapeutic development. As pipelines expand and modalities diversify, organizations are seeking specialized partners to accelerate timelines, ensure regulatory compliance, and optimize cost structures. This executive summary introduces a holistic exploration of market forces, regulatory headwinds, and evolving business models that collectively craft the path forward for both emerging biotech ventures and established pharmaceutical giants.

Through rigorous analysis of service offerings spanning analytical testing to clinical development phases, coupled with an in-depth segmentation by molecule type, application, and end-user demands, this report illuminates how stakeholder priorities are shifting towards flexibility, integrated solutions, and strategic outsourcing. By weaving in the implications of new tariff regimes and regional growth dynamics, the introduction sets the stage for a comprehensive narrative that empowers decision-makers to navigate uncertainties, capitalize on emerging opportunities, and foster collaborative ecosystems that drive therapeutic breakthroughs.

Evolving Dynamics Reshaping Contract Research and Manufacturing

The contract research and manufacturing sector is undergoing transformative shifts that are redefining traditional outsourcing paradigms. Rapid advances in cell culture platforms and process development technologies have elevated expectations for speed and scalability. Meanwhile, the advent of next-generation modalities such as CAR T therapies and viral vector gene delivery is demanding specialized preclinical and clinical development capabilities that were once considered niche. This convergence of innovation has spurred a wave of strategic partnerships and targeted investments, as organizations seek to align with providers capable of end-to-end delivery from formulation through fill-finish.

Concurrently, the rise of biosimilars and novel biologics is reshaping capacity planning and risk management priorities. Service providers are extending their portfolios beyond core analytical testing to encompass comprehensive process validation, stability studies, and GMP manufacturing for both large and small molecules. Outsourcing strategies have evolved from single-phase engagements to longitudinal collaborations, where integrated project management and digital data platforms ensure transparency and compliance across geographically dispersed operations. These shifts underscore the importance of agility, technical depth, and a proactive approach to emerging regulatory expectations.

Navigating the 2025 United States Tariff Wave

With the introduction of new tariff measures scheduled for 2025, biopharmaceutical outsourcing strategies must adapt to a redefined cost environment. These tariffs will impact a broad range of imported materials, equipment, and intermediate compounds, adding complexity to supply chain planning. Organizations that rely heavily on overseas sourcing for reagents or rely on contract manufacturing facilities abroad will need to re-evaluate total landed costs and consider near-shoring or on-shoring options to mitigate exposure. This scenario creates a competitive advantage for regions with established manufacturing hubs and favorable trade agreements.

Moreover, the cumulative impact of tariffs extends beyond direct input costs. Potential delays in customs clearance processes can disrupt project timelines, affecting clinical trial enrollment and regulatory submissions. Providers with robust domestic capacity and flexible supply networks will be better positioned to absorb these shocks and maintain continuity. This environment incentivizes long-term contractual agreements with built-in inflation adjustments and collaborative risk-sharing models. As industry leaders refine their outsourcing frameworks, understanding the full spectrum of tariff implications will be critical for sustaining operational efficiency and protecting profit margins.

Unveiling Market Nuances Across Service Product Application and End User

The market’s complexity becomes clear when analyzed through the prism of service type, product type, application, and end-user profiles. Service offerings span from high-throughput analytical testing to specialized cell culture and comprehensive clinical development phases, while fill-finish, formulation, and process development capabilities create a continuum of support throughout the drug lifecycle. In the realm of product type, large molecules such as biologics and biosimilars-encompassing monoclonal antibodies, recombinant proteins, and vaccines-require distinct operational frameworks compared to small molecules, whether generics or new chemical entities. Each category demands tailored quality controls and capacity planning.

Applications range from cutting-edge cell therapies, differentiated into CAR T and stem cell platforms, to gene therapies using both non-viral and viral vectors, reflecting the nuanced validation and regulatory pathways each modality requires. Monoclonal antibodies, with their bispecific, conjugated, and naked variants, demand rigorous characterization, while recombinant proteins such as enzymes, growth factors, and hormones call for precise expression and purification processes. Therapeutic vaccines-spanning inactivated, live attenuated, mRNA, and subunit formats-introduce further complexity in stability and cold-chain logistics. Finally, the end users-large and small biotechnology companies, full-service and niche contract research organizations, tiered pharmaceutical companies, and academic or government research institutions-shape demand for flexible engagement models and integrated project management solutions.

Regional Epicenters Driving Global Biopharmaceutical Outsourcing

Regional dynamics are a key determinant of strategic positioning in the contract research and manufacturing sector. In the Americas, established hubs in North America continue to lead in innovation and capacity, underpinned by strong regulatory frameworks and deep expertise in clinical development. Biotech clusters across the U.S. offer proximity to academic research centers and venture capital, driving demand for end-to-end outsourcing partnerships. Latin America is emerging as a cost-effective alternative for process development and analytical testing, leveraging favorable labor costs and local talent pools.

Europe, Middle East & Africa present a diverse tapestry of regulatory landscapes and market maturity. Western European countries maintain leadership in biologics manufacturing and regulatory harmonization, while emerging markets in Eastern Europe and parts of the Middle East are investing heavily in facility expansions and workforce training. Africa’s nascent infrastructure and growing health initiatives suggest long-term opportunities in vaccine production and clinical research. Asia-Pacific remains a powerhouse of manufacturing capacity and competitive pricing, with major investments in both large molecule and small molecule capabilities across China, India, Japan, and Southeast Asia. Collaborative frameworks and free trade zones further enhance the region’s attractiveness for integrated development and commercial manufacturing.

Leading Players Steering Industry Innovation and Partnerships

Key players in the contract research and manufacturing domain are differentiating through strategic alliances, capacity expansions, and digital innovation. Leading contract development and manufacturing organizations have invested in single-use bioreactor platforms, advanced analytics, and modular cleanroom designs to optimize throughput and ensure rapid scalability. At the same time, specialized contract research organizations are broadening their footprint by adding cell and gene therapy services, reflecting the therapeutic revolution underway.

Mergers and acquisitions continue to redefine competitive dynamics, enabling providers to offer end-to-end solutions from process development through late-stage clinical manufacturing. Investments in proprietary data management systems and AI-driven process optimization tools are enhancing predictive maintenance and batch consistency. Additionally, strategic partnerships between service providers and technology innovators are accelerating the adoption of continuous manufacturing and in silico modeling, further reducing cycle times. Through these multifaceted initiatives, leading organizations are establishing themselves as comprehensive partners capable of navigating complex regulatory landscapes while fostering scientific advancement.

Strategic Imperatives for Industry Stakeholders

Industry stakeholders must adopt a forward-looking mindset to capitalize on emerging trends and mitigate disruptive forces. First, diversifying supply chains through regional manufacturing hubs will reduce exposure to trade policy fluctuations and logistical bottlenecks. Building partnerships with providers offering modular, scalable facilities can ensure capacity agility and accelerated time to market. Second, investing in digital platforms that integrate project management, quality oversight, and real-time analytics will promote transparency and drive operational excellence.

Third, organizations should prioritize collaboration with partners possessing deep expertise in novel modalities, particularly cell and gene therapies, as well as advanced biologic constructs. Leveraging joint development agreements and shared risk models can expedite innovation cycles. Fourth, embedding sustainability metrics into operational charters will address growing stakeholder expectations around environmental responsibility. Finally, nurturing talent through cross-functional training and digital literacy will strengthen organizational resilience and adaptability as the industry evolves.

Rigorous Methodology Underpinning Comprehensive Market Analysis

The insights presented in this report are underpinned by a rigorous research framework that combines quantitative data analysis with qualitative expert consultations. Primary research involved in-depth interviews with senior executives at leading biotechnology firms, pharmaceutical companies, and contract service providers, supplemented by surveys capturing strategic priorities and capacity utilization. Secondary research encompassed a comprehensive review of regulatory filings, patent databases, academic publications, and industry white papers to map technological advancements and competitive landscapes.

Market segmentation parameters were defined through iterative validation with subject-matter experts, ensuring that service type, product category, application, and end-user classifications reflect real-world engagement models. Regional dynamics were analyzed using trade data, facility expansion announcements, and country-specific regulatory assessments. Finally, data integrity was maintained through cross-referencing multiple sources and applying statistical checks to identify anomalies. This methodological rigor ensures that the analysis is both robust and actionable for decision-makers seeking to navigate the complex biopharmaceutical outsourcing ecosystem.

Synthesis of Market Trajectory and Strategic Pathways

The interplay of technological innovation, regulatory evolution, and geopolitical shifts is redefining the contours of the biopharmaceutical contract research and manufacturing market. As emerging modalities demand specialized capabilities, and tariff landscapes introduce new cost considerations, strategic partnerships and digital integration emerge as critical success factors. Regional hubs will continue to compete for investment, with the Americas, Europe Middle East & Africa, and Asia-Pacific each offering distinct advantages in capacity, cost, and regulatory alignment.

Organizations that embrace flexible outsourcing structures, invest in advanced analytics, and foster collaborative development models will be best positioned to accelerate therapeutic breakthroughs while maintaining operational resilience. The synthesis of segmentation insights, regional analysis, and competitive dynamics outlined in this summary provides a roadmap for stakeholders to navigate a rapidly evolving market. By leveraging these insights, industry leaders can make informed decisions that drive innovation, optimize resources, and deliver life-saving therapies to patients worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Service Type
    • Analytical
    • Cell Culture
    • Clinical Development
      • Phase I
      • Phase II
      • Phase III
    • Fill-Finish
    • Formulation
    • Preclinical Development
    • Process Development
  • Product Type
    • Large Molecule
      • Biologics
        • Monoclonal Antibodies
        • Recombinant Proteins
        • Vaccines
      • Biosimilars
    • Small Molecule
      • Generics
      • New Chemical Entities
  • Application
    • Cell Therapies
      • CAR T
      • Stem Cell
    • Gene Therapies
      • Non Viral
      • Viral Vector
    • Monoclonal Antibodies
      • Bispecific
      • Conjugated
      • Naked
    • Recombinant Proteins
      • Enzymes
      • Growth Factors
      • Hormones
    • Vaccines
      • Inactivated
      • Live Attenuated
      • mRNA
      • Subunit
  • End User
    • Biotechnology Companies
      • Large Biotech
      • Small Biotech
    • CROs
      • Full Service
      • Niche Service
    • Pharmaceutical Companies
      • Tier I
      • Tier II
      • Tier III
    • Research Institutions
      • Academia
      • Government
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • IQVIA Services Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • Syneos Health, Inc.
  • Charles River Laboratories International, Inc.
  • ICON plc
  • Catalent, Inc.
  • Parexel International Corporation
  • WuXi Biologics Co., Ltd.
  • Samsung Biologics Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biopharmaceutical CMO & CRO Market, by Service Type
8.1. Introduction
8.2. Analytical
8.3. Cell Culture
8.4. Clinical Development
8.4.1. Phase I
8.4.2. Phase II
8.4.3. Phase III
8.5. Fill-Finish
8.6. Formulation
8.7. Preclinical Development
8.8. Process Development
9. Biopharmaceutical CMO & CRO Market, by Product Type
9.1. Introduction
9.2. Large Molecule
9.2.1. Biologics
9.2.1.1. Monoclonal Antibodies
9.2.1.2. Recombinant Proteins
9.2.1.3. Vaccines
9.2.2. Biosimilars
9.3. Small Molecule
9.3.1. Generics
9.3.2. New Chemical Entities
10. Biopharmaceutical CMO & CRO Market, by Application
10.1. Introduction
10.2. Cell Therapies
10.2.1. CAR T
10.2.2. Stem Cell
10.3. Gene Therapies
10.3.1. Non Viral
10.3.2. Viral Vector
10.4. Monoclonal Antibodies
10.4.1. Bispecific
10.4.2. Conjugated
10.4.3. Naked
10.5. Recombinant Proteins
10.5.1. Enzymes
10.5.2. Growth Factors
10.5.3. Hormones
10.6. Vaccines
10.6.1. Inactivated
10.6.2. Live Attenuated
10.6.3. mRNA
10.6.4. Subunit
11. Biopharmaceutical CMO & CRO Market, by End User
11.1. Introduction
11.2. Biotechnology Companies
11.2.1. Large Biotech
11.2.2. Small Biotech
11.3. CROs
11.3.1. Full Service
11.3.2. Niche Service
11.4. Pharmaceutical Companies
11.4.1. Tier I
11.4.2. Tier II
11.4.3. Tier III
11.5. Research Institutions
11.5.1. Academia
11.5.2. Government
12. Americas Biopharmaceutical CMO & CRO Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Biopharmaceutical CMO & CRO Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Biopharmaceutical CMO & CRO Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. IQVIA Services Inc.
15.3.2. Laboratory Corporation of America Holdings
15.3.3. Lonza Group AG
15.3.4. Syneos Health, Inc.
15.3.5. Charles River Laboratories International, Inc.
15.3.6. ICON plc
15.3.7. Catalent, Inc.
15.3.8. Parexel International Corporation
15.3.9. WuXi Biologics Co., Ltd.
15.3.10. Samsung Biologics Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BIOPHARMACEUTICAL CMO & CRO MARKET MULTI-CURRENCY
FIGURE 2. BIOPHARMACEUTICAL CMO & CRO MARKET MULTI-LANGUAGE
FIGURE 3. BIOPHARMACEUTICAL CMO & CRO MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIOPHARMACEUTICAL CMO & CRO MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIOPHARMACEUTICAL CMO & CRO MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOPHARMACEUTICAL CMO & CRO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ANALYTICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FILL-FINISH, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENERICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NEW CHEMICAL ENTITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CAR T, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STEM CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NON VIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BISPECIFIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONJUGATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NAKED, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE BIOTECH, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL BIOTECH, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FULL SERVICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NICHE SERVICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER I, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER II, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER III, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ACADEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GOVERNMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 110. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 111. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 112. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 114. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 115. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 116. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 118. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 119. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 120. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 121. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 122. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 124. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 125. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 126. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 129. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 133. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 135. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 141. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 213. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 214. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 215. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 217. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 218. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 219. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 221. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 222. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 223. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 224. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 225. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 227. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 228. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 229. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 230. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 231. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 232. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 234. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 235. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 236. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 238. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 239. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 240. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 241. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 242. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 244. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 245. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 246. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 264. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 265. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 266. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 267. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 268. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 269. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 270. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 272. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 273. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 274. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 275. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 276. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 278. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 279. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 280. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 281. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 282. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 283. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 285. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 286. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 287. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 289. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 290. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 291. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 292. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 293. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 295. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2030 (USD MILLION)
TABLE 296. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 297. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2030 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACC

Companies Mentioned

The companies profiled in this Biopharmaceutical CMO & CRO market report include:
  • IQVIA Services Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • Syneos Health, Inc.
  • Charles River Laboratories International, Inc.
  • ICON plc
  • Catalent, Inc.
  • Parexel International Corporation
  • WuXi Biologics Co., Ltd.
  • Samsung Biologics Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 113.74 Billion
Forecasted Market Value ( USD ) by 2030 $ 261.14 Billion
Compound Annual Growth Rate18.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Biopharmaceutical CMO and CRO Market Report 2025 - Product Image

Biopharmaceutical CMO and CRO Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Biopharmaceutical CMO And CRO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Biopharmaceutical CMO And CRO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 120 Pages
  • Global
From
Preclinical CRO Market by Service Type, Stage Of Development, Model Type, Application, End User - Global Forecast to 2030 - Product Image

Preclinical CRO Market by Service Type, Stage Of Development, Model Type, Application, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor, Others), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor, Others), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Preclinical CRO Market Report by Service, End Use, and Region 2024-2032 - Product Image

Preclinical CRO Market Report by Service, End Use, and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.